miR-129-5p attenuates cell proliferation and epithelial mesenchymal transition via HMGB1 in gastric cancer

被引:51
|
作者
Wang, Shaocheng [1 ]
Chen, Yanyan [1 ]
Yu, Xiongfei [1 ]
Lu, Yimin [1 ]
Wang, Haoao [1 ]
Wu, Fusheng [1 ]
Teng, Lisong [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Surg Oncol, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China
关键词
miR-129-5p; Gastric cancer; Epithelial mesenchymal transition; HMGB1; Proliferation; GROUP BOX 1; GROWTH; MICROMETASTASIS; METASTASIS;
D O I
10.1016/j.prp.2018.12.024
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: The miR-129-5p has been reported to be aberrant expression and exert vital roles in tumor progression of various malignancies. However, the effects on EMT in gastric cancer and its precise molecular mechanism in gastric cancer remain unclear. Methods and materials: RT-qPCR was performed to evaluate the expression level of miR-129-5p and HMGB1 in cell lines. Cell proliferation was detected via CCK-8. The epithelial mesenchymal transition (EMT) related proteins and the expression of HMGB1 were detected by western blot analysis. Luciferase assays were used to validate binding seeds between miR-129-5p and HMGB1. Results: miR-129-5p was downregulated in gastric cancer cells compared with GES-1. At the same time EMT was promoted in gastric cancer cells compared to GES-1. Overexpression of miR-129-5p inhibited EMT and proliferation. MiR-129-5p negatively and directly targeted HMGB1. HMGB1 was upregulated in gastric cancer cells and HMGB1 knocked-down inhibited EMT and cell proliferation. Conclusion: Taken together, upregulation of miR-129-5p associated with gastric cancer proliferation and EMT, and serves as a potential diagnostic and therapeutic target via miR-129-5p/HMGB1 pathway in gastric cancer.
引用
收藏
页码:676 / 682
页数:7
相关论文
共 50 条
  • [1] MiR-129-5p inhibits proliferation of gastric cancer cells through targeted inhibition on HMGB1 expression
    Feng, J.
    Guo, J.
    Wang, J-P
    Chai, B-F
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (07) : 3665 - 3673
  • [2] LncRNA MALAT1 induces colon cancer development by regulating miR-129-5p/HMGB1 axis
    Wu, Qiong
    Meng, Wen-Ying
    Jie, Ying
    Zhao, Haijian
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (09) : 6750 - 6757
  • [3] miR-129-5p inhibits prostate cancer proliferation via targeting ETV1
    Gao, Ge
    Xiu, Dianhui
    Yang, Bin
    Sun, Daju
    Wei, Xin
    Ding, Youpeng
    Ma, Yanan
    Wang, Zhixin
    ONCOTARGETS AND THERAPY, 2019, 12 : 3531 - 3544
  • [4] mir-129-5p Attenuates Irradiation-Induced Autophagy and Decreases Radioresistance of Breast Cancer Cells by Targeting HMGB1
    Luo, Jing
    Chen, Jie
    He, Li
    MEDICAL SCIENCE MONITOR, 2015, 21 : 4122 - 4129
  • [5] MiR-129-5p suppresses gastric cancer cell invasion and proliferation by inhibiting COL1A1
    Wang, Quan
    Yu, Jinhai
    BIOCHEMISTRY AND CELL BIOLOGY, 2018, 96 (01) : 19 - 25
  • [6] MiR-129-5p influences the progression of gastric cancer cells through interacting with SPOCK1
    Yan, Lei
    Sun, Kai
    Liu, Yang
    Liang, Jun
    Cai, Kerui
    Gui, Jinqiu
    TUMOR BIOLOGY, 2017, 39 (06)
  • [7] MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p
    Liu, Ke
    Huang, Jun
    Ni, Jiangdong
    Song, Deye
    Ding, Muliang
    Wang, Junjie
    Huang, Xianzhe
    Li, Wenzhao
    CELL CYCLE, 2017, 16 (06) : 578 - 587
  • [8] Role of miR-129-5p in Proliferation and Invasion of Prostate Cancer Cells
    Xu, Yang
    Wang, Jing
    Wang, Bin
    Gao, Qingqiang
    Yu, Wen
    Xu, Zhipeng
    INTERNATIONAL JOURNAL OF HUMAN GENETICS, 2023, 23 (04) : 207 - 215
  • [9] MEG3 aggravates hypoxia/reoxygenation induced apoptosis of renal tubular epithelial cells via the miR-129-5p/HMGB1 axis
    Mao, Huihui
    Huang, Qiao
    Liu, Ying
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2021, 35 (02)
  • [10] The Role of miR-129-5p in Cancer: A Novel Therapeutic Target
    Xu, Shan
    Li, Wei
    Wu, Jing
    Lu, Yuru
    Xie, Ming
    Li, Yanlan
    Zou, Juan
    Zeng, Tiebing
    Ling, Hui
    CURRENT MOLECULAR PHARMACOLOGY, 2022, 15 (04) : 647 - 657